Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment

NACompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2022

Conditions
Colorectal Cancer
Interventions
GENETIC

ccfDNA analysis

The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance

Trial Locations (19)

15000

Aurillac Hospital, Aurillac

19000

Les Cèdres clinical, Brive-la-Gaillarde

Brive Hospital, Brivé

23000

Gueret Hospital, Guéret

La marche clinical, Guéret

Sainte feyre Hospital, Sainte-Feyre

24000

Perigueux clinical, Périgueux

Périgueux Hospital, Périgueux

33000

Bergonie institute, Bordeaux

Bordeaux University Hospital, Bordeaux

34000

Montpellier Institute, Montpellier

Montpellier University Hospital, Montpellier

46000

Cahors Hospital, Cahors

75012

Saint Antoine AP-HP, Paris

87000

Saint Junien Hospital, Saint-Junien

Unknown

Clermont Ferrand University Hospital, Clermont-Ferrand

87 042

Limoges Hospital, Limoges

03000

Moulins Hospital, Moulins

03200

Vichy Hospital, Vichy

All Listed Sponsors
lead

University Hospital, Limoges

OTHER

NCT02813928 - Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment | Biotech Hunter | Biotech Hunter